Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth [0.03%]
Tomohiro Shibata,Shabir Bhat,DuoYao Cao et al.
Tomohiro Shibata et al.
The potential of the immune system to decrease cancer progression is widely recognized and has led to the development of innovative anti-cancer immunotherapies. Here, we studied human macrophages derived from genetically engineered iPSCs (i...
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial [0.03%]
Junlong Wu,Xinghai Li,Chengyuan Gu et al.
Junlong Wu et al.
Metastatic castration-resistant prostate cancer (mCRPC) after treatment with docetaxel and androgen receptor signaling inhibitors (ARSIs) has limited treatment options. Although enzalutamide has shown activity after abiraterone and docetaxe...
Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy [0.03%]
Joo-Yoon Chung,Jisu Hong,Su-Min Yee et al.
Joo-Yoon Chung et al.
Chimeric antigen receptor (CAR)-based immunotherapies against solid tumors face two major hurdles, the "decoy effect" of shedding antigens that sequester CARs, and the limited persistence of immune effectors within the immunosuppressive tum...
Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond [0.03%]
Mads Hald Andersen
Mads Hald Andersen
Immune modulatory vaccines (IMVs) are an emerging class of immunotherapies designed to expand anti-regulatory T cells (anti-Tregs) that selectively target immunosuppressive elements within the tumor microenvironment (TME). Unlike convention...
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study [0.03%]
Wenwei Yang,Jing Zhang,Ping Liang et al.
Wenwei Yang et al.
Patients diagnosed with metastatic colorectal cancer (mCRC) face a constrained therapeutic landscape following the failure of initial treatment. This multicenter, single-arm, phase II trial (NCT06202001) aimed to assess the efficacy and saf...
Soura Chakraborty,Jhuma Pramanik,Gustavo Alviter-Raymundo et al.
Soura Chakraborty et al.
Tumors foster an immunosuppressive microenvironment to evade the antitumor immune response. However, the influence of intratumoral immunosuppressive steroids on tumor-infiltrating natural killer (NK) cells and their implications for effecti...
BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis [0.03%]
Ting Wu,Shuang Qi,Chenliang Shi et al.
Ting Wu et al.
Chemotherapy resistance remains a critical bottleneck limiting its clinical efficacy in small cell lung cancer (SCLC), with its core mechanisms and targeted intervention strategies urgently requiring breakthroughs. Our study revealed that t...
Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma [0.03%]
Minghao Xu,Yimin Zheng,Longtao Zhao et al.
Minghao Xu et al.
Resistance to lenvatinib remains a major barrier in the treatment of advanced hepatocellular carcinoma (HCC), underscoring the urgent need to elucidate the underlying mechanisms and identify actionable therapeutic targets. In this study, we...
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study [0.03%]
Shuang Huang,Feng Liu,Song Qu et al.
Shuang Huang et al.
In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomise...